|
 Basal cell carcinoma can be highly disfiguring and life-threatening
in its advanced stages. The number of people with the illness is on
the rise as the global population ages and people become
increasingly exposed to ultraviolet rays.
The Phase II trial assessed the safety and efficacy of two oral
doses of Novartis' drug LDE225 in patients with locally advanced or
metastatic basal cell carcinoma.
Results of the mid-stage study presented at the American Society of
Clinical Oncology meeting in Chicago on Sunday found patients had
marked and sustained tumour shrinkage after a median follow-up of
13.9 months, Novartis said.
Alessandro Riva, head of Novartis Oncology Development and Medical
Affairs, said the data would form the basis for filings for approval
with global health regulators.
(Reporting by Caroline Copley; editing by Jane Baird)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
